HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Lon S Schneider Selected Research

Citalopram

1/2017Characterizing Highly Benefited Patients in Randomized Clinical Trials.
5/2016Effects of Citalopram on Neuropsychiatric Symptoms in Alzheimer's Dementia: Evidence From the CitAD Study.
5/2016Heterogeneity of Treatment Response to Citalopram for Patients With Alzheimer's Disease With Aggression or Agitation: The CitAD Randomized Clinical Trial.
3/2016Citalopram for the Treatment of Agitation in Alzheimer Dementia: Genetic Influences.
3/2016Sedation mediates part of Citalopram's effect on agitation in Alzheimer's disease.
2/2016A population pharmacokinetic model for R- and S-citalopram and desmethylcitalopram in Alzheimer's disease patients with agitation.
1/2016Principal components analysis of agitation outcomes in Alzheimer's disease.
1/2016R- and S-citalopram concentrations have differential effects on neuropsychiatric scores in elders with dementia and agitation.
12/2015Change in agitation in Alzheimer's disease in the placebo arm of a nine-week controlled trial.
11/2015Time to Response to Citalopram Treatment for Agitation in Alzheimer Disease.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Lon S Schneider Research Topics

Disease

107Alzheimer Disease (Alzheimer's Disease)
04/2022 - 01/2003
31Dementia (Dementias)
01/2022 - 07/2003
27Cognitive Dysfunction
08/2021 - 01/2004
12Psychotic Disorders (Schizoaffective Disorder)
01/2018 - 01/2003
4Schizophrenia (Dementia Praecox)
11/2011 - 02/2008
4Vascular Dementia (Subcortical Arteriosclerotic Encephalopathy)
09/2007 - 04/2002
3Disease Progression
01/2017 - 08/2011
3Body Weight (Weight, Body)
02/2016 - 05/2009
3Sleepiness
08/2011 - 03/2006
2Atrophy
01/2022 - 10/2019
2Amyloidosis
08/2021 - 01/2021
2Hallucinations (Hallucination)
05/2016 - 01/2004
2Major Depressive Disorder (Major Depressive Disorders)
06/2013 - 09/2003
2Diarrhea
08/2011 - 04/2010
2Dizziness (Lightheadedness)
04/2010 - 12/2009
1Proteostasis Deficiencies
01/2022
1Neurodegenerative Diseases (Neurodegenerative Disease)
01/2021
1Brain Diseases (Brain Disorder)
01/2021
1Frontotemporal Dementia (Semantic Dementia)
01/2021
1Memory Disorders (Memory Loss)
11/2019
1Hypoxia (Hypoxemia)
01/2018
1Mental Disorders (Mental Disorder)
05/2016
1Delirium
05/2015
1Epistaxis (Nosebleed)
07/2014
1Progressive Supranuclear Palsy (Steele Richardson Olszewski Syndrome)
07/2014

Drug/Important Bio-Agent (IBA)

18Biomarkers (Surrogate Marker)IBA
01/2022 - 03/2010
18Antipsychotic Agents (Antipsychotics)IBA
01/2016 - 01/2003
15Pharmaceutical PreparationsIBA
01/2022 - 02/2003
13CitalopramFDA LinkGeneric
01/2017 - 01/2012
10Risperidone (Risperdal Consta)FDA LinkGeneric
01/2012 - 07/2003
9Amyloid (Amyloid Fibrils)IBA
08/2021 - 01/2011
8Memantine (Namenda)FDA Link
11/2019 - 01/2007
8Cholinesterase Inhibitors (Anticholinesterases)IBA
11/2018 - 05/2003
8Olanzapine (Zyprexa)FDA Link
01/2012 - 10/2005
7Donepezil (Aricept)FDA LinkGeneric
11/2019 - 06/2004
7Antidepressive Agents (Antidepressants)IBA
05/2015 - 11/2006
6Apolipoproteins E (ApoE)IBA
01/2022 - 05/2014
6Sertraline (Zoloft)FDA LinkGeneric
01/2014 - 11/2006
5Apolipoprotein E4IBA
09/2020 - 01/2016
5Quetiapine Fumarate (Seroquel)FDA Link
01/2012 - 10/2005
4ApolipoproteinsIBA
01/2022 - 05/2014
4Proteins (Proteins, Gene)FDA Link
01/2021 - 10/2011
3Biological ProductsIBA
01/2021 - 03/2015
3Amyloid beta-PeptidesIBA
01/2021 - 12/2009
3Valproic Acid (Depakote)FDA LinkGeneric
05/2015 - 08/2011
2LipidsIBA
04/2022 - 05/2009
2Pregnanolone (Allopregnanolone)IBA
01/2022 - 01/2020
2NeurosteroidsIBA
01/2022 - 01/2020
2Peptides (Polypeptides)IBA
08/2021 - 01/2011
2Investigational DrugsIBA
01/2021 - 01/2016
2Docosahexaenoic AcidsIBA
09/2020 - 03/2017
2Therapeutic UsesIBA
01/2020 - 05/2016
2Rivastigmine (Exelon)FDA LinkGeneric
11/2019 - 09/2007
2ziprasidone (Geodon)FDA Link
11/2011 - 10/2005
2Selective Serotonin Reuptake Inhibitors (Serotonin Reuptake Inhibitors)IBA
04/2010 - 11/2006
2Ginkgo biloba extract (Rokan)IBA
11/2008 - 12/2005
1HDL LipoproteinsIBA
04/2022
1Glucagon-Like Peptide 1 (GLP 1)IBA
01/2022
1Glucagon-Like Peptide-1 Receptor AgonistsIBA
01/2022
1aducanumabIBA
11/2021
1AcidsIBA
08/2021
14- (N- methylamino)- 4'- (2- (2- (2- fluoroethoxy)ethoxy)ethoxy)stilbeneIBA
08/2021
1florbetapirIBA
08/2021
1EnzymesIBA
01/2021
1Nucleic AcidsIBA
01/2021
1Pioglitazone (Actos)FDA Link
01/2021
1Eicosapentaenoic AcidIBA
09/2020
1Hormones (Hormone)IBA
01/2020
1Cyclophilin AIBA
01/2020
1Matrix Metalloproteinase 9 (Gelatinase B)IBA
01/2020
1Sigma-1 ReceptorIBA
11/2019
1maleic acid (maleate)IBA
11/2019
1AMPA Receptors (AMPA Receptor)IBA
11/2019
1EscitalopramFDA Link
11/2019
1(N-propargyl-(3R) aminoindan-5-yl)-ethyl methyl carbamateIBA
10/2019
1sigma-2 receptorIBA
01/2019
1pimavanserinIBA
01/2018
1phenserineIBA
01/2018
1crenezumabIBA
01/2018
1Phospholipases (Phospholipase)IBA
03/2017
1Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA
02/2017
1Simvastatin (Zocor)FDA LinkGeneric
02/2017
1CholesterolIBA
02/2017
1Methylene Blue (Methylthioninium Chloride)FDA Link
12/2016
1Lorazepam (Ativan)FDA LinkGeneric
05/2016
1Hypnotics and Sedatives (Sedatives)IBA
03/2016
1desmethylcitalopramIBA
02/2016
1Threonine (L-Threonine)FDA Link
02/2015
1Alanine (L-Alanine)FDA Link
02/2015
1(2- (6- fluoro- 1H- indol- 3- yl)- ethyl)- (3- (2,2,3,3- tetrafluoropropoxy)benzyl)amineIBA
11/2014
1davunetideIBA
07/2014
1Indicators and Reagents (Reagents)IBA
07/2013

Therapy/Procedure

11Therapeutics
01/2022 - 11/2006
4Activities of Daily Living (ADL)
12/2016 - 07/2009
4Home Nursing (Nursing, Home)
04/2012 - 01/2004
3Precision Medicine
01/2021 - 01/2018
2Secondary Prevention
01/2021 - 07/2013
1Tertiary Prevention
01/2022
1Long-Term Care
05/2016
1Duration of Therapy
04/2013